Alterity Board Changes
Filed with ASX · · 3 pages · English
Alterity Therapeutics Limited ACN 080 699 065 (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) announces a series of Board changes ahead of its Annual General Meeting of Shareholders on Friday 21st November, designed to align with the Company’s next phase of growth as it advances towards Phase 3 clinical development. Mr Geoffrey Kempler, founding shareholder, former Chief Executive Officer a
Alterity Therapeutics Ltd. on 6ix
In the deck
Earlier from Alterity Therapeutics
- Alterity Therapeutics to Present at the Bell Potter Healthcare Virtual Conference
- Alterity Therapeutics Presents Promising Impact of ATH434 on Orthostatic Hypotension and Disease Progression in MSA at the 36th International Symposium on the Autonomic Nervous System
- Alterity Therapeutics Presents Promising Impact of ATH434 on Orthostatic Hypotension and Disease Progression in MSAat the 36th International Symposium on the Autonomic Nervous System
- Appendix 4C – Q1 FY26 Quarterly Cash Flow Report
- Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson’s Disease and Movement Disorders
Later from Alterity Therapeutics
- Alterity Therapeutics Issues Shareholder Letter Highlighting 2025 Progress and Key Objectives for 2026
- Quarterly Activities/Appendix 4C Cash Flow Report
- Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update
- Half Yearly Report and Accounts
- Alterity Therapeutics Recognizes Multiple System Atrophy (MSA) Awareness Month in March and the Urgent Need for Disease-Modifying Treatments
Follow Alterity Therapeutics into a list and get an email when it puts out news.
Follow Alterity Therapeutics